Archives
-
EPZ5676: DOT1L Inhibition Beyond Leukemia
2026-10-01
Explore how EPZ5676, a highly selective DOT1L inhibitor, connects H3K79 methylation biology in MLL-rearranged leukemia with emerging innate immune mechanisms in multiple myeloma. This guide translates the evidence into practical assay and interpretation decisions.
-
Ganetespib: Assay Logic for Hsp90 Stress Biology
2026-10-01
Ganetespib and STA-9090 provide a precise model for studying Hsp90 chaperone disruption, client-protein loss, and tumor-cell phenotypes. This article develops a causality-focused assay framework informed by a recent NINJ1 secretion study, while clearly separating established evidence from cross-domain hypotheses.
-
(-)-JQ1 and the Logic of BET Control in AML
2026-09-30
A translational framework for using (-)-JQ1, the inactive JQ1 stereoisomer, to distinguish BET-dependent transcriptional effects from vehicle, off-target, and model-specific signals in inv(16) acute myeloid leukemia research.
-
FGFR Signaling in Guinea Pig Penile Development
2026-09-30
A 2025 Cells study explains why guinea pigs form an open urethral groove whereas mice primarily canalize a urethral plate, linking the difference to developmental timing and differential Shh, Fgf10, and Fgfr2 expression. Comparative gene mapping and organ-culture perturbation identify a testable relationship between the FGFR signaling pathway, preputial growth, and urethral morphogenesis.
-
miR-24-3p in Doxorubicin-Induced Heart Failure
2026-09-29
The reference study identifies miR-24-3p as a negative regulator of cardiac function in doxorubicin-induced heart failure and links its effects to the Sp1/PI3K signaling axis. By combining rat and H9c2 models with inhibitor experiments, miR-24-3p manipulation, and dual-luciferase validation, the work provides a mechanistic framework for studying apoptosis and oxidative stress in myocardial injury.
-
NMN, SIRT3, and Diabetic Myocardial Fibrosis
2026-09-29
A 2026 mouse study reports that nicotinamide mononucleotide reduced diabetes-associated myocardial fibrosis while increasing SIRT3 and lowering GSK3β acetylation and Smad3 phosphorylation. Its main contribution is a testable connection between NAD+ metabolism, protein deacetylation, and cardiac remodeling, although the proposed mechanism remains preclinical rather than clinically established.
-
Decitabine Primes Progenitor Tex for Anti–PD-1 Therapy
2026-09-28
A 2023 Journal of Clinical Investigation study shows that low-dose Decitabine can improve anti–PD-1 responses by expanding and functionally preserving CD8+ progenitor exhausted T cells. The work connects DNA hypomethylation with sustained JunD/AP-1 activity, offering a mechanistic framework for epigenetic priming in tumor immunology research.
-
5-hme-dCTP: From Substrate to Stress Biology
2026-09-28
A strategic guide to using 5-hme-dCTP in epigenetic DNA modification research, distinguishing controlled substrate experiments from endogenous 5hmC mapping and translating rice drought findings into sharper assay decisions.
-
UHRF1–TGM2 Signaling in Senile Osteoporosis
2026-09-27
A 2026 study connects reduced UHRF1-associated DNA 5-methylcytosine, super-enhancer redistribution, and altered TGM2-regulated autophagic flux to impaired osteogenesis in senile osteoporosis. Its multi-omics and mouse-model findings identify the UHRF1–TGM2 axis as a candidate for further study, while leaving important questions about mechanism, human relevance, and therapeutic translation.
-
Clathrin-Mediated Entry of Type III Grass Carp Reovirus
2026-09-26
Wang et al. used pharmacological inhibitors, transmission electron microscopy, and quantitative PCR to investigate how genotype III grass carp reovirus enters cultured grass carp cells. Their results support a dynamin-dependent, clathrin-mediated entry route, while the lack of inhibition by amiloride shows that this particular viral entry process was not detectably sensitive to the compound under the tested conditions.
-
3-Deazaadenosine: Practical Cell Assay Guidance
2026-09-25
A scenario-driven guide to using 3-Deazaadenosine (SKU B6121) in methylation-focused cell experiments, with practical guidance for assay controls, handling, and interpretation. It distinguishes reported product properties from workflow recommendations and explains why viability changes should not be treated as direct evidence of cell death or antiviral activity.
-
5-AzaC and EZH2 Inhibition Restore Viral Mimicry in GBM
2026-09-25
A 2025 study reports that PTEN deficiency suppresses the ERV–MAVS–type I interferon axis in glioblastoma, contributing to an immunosuppressive tumor environment. In the study, 5-azacytidine alone did not overcome this state, whereas combining it with EZH2 inhibition reduced H3K27me3, promoted ERV expression, and strengthened antitumor immune responses.
-
CD44 Rewires Metabolism in IDH-Mutant Leukemia
2026-09-24
The study identifies CD44 as a metabolic dependency in IDH-mutant leukemia: it shifts glucose metabolism to sustain NADPH production, supporting ongoing R-2-hydroxyglutarate synthesis. The findings provide a preclinical rationale for testing CD44 blockade alongside mutant-IDH inhibition, while leaving clinical benefit and transferability to different leukemia contexts to be established.
-
Oltipraz, Nrf2 and the Translational Redox Gap
2026-09-24
How Oltipraz can help translational researchers test Nrf2-linked cellular defense—and how to interpret its relevance alongside emerging MASLD findings on autophagy and ferroptosis.
-
AG-221 and the IDH2 Leukemia Feedback Loop
2026-09-23
AG-221 (Enasidenib) offers a way to test how mutant IDH2 sustains leukemia-associated 2-hydroxyglutarate production. This article connects target engagement to CD44-driven metabolic adaptation and shows how to interpret metabolite, differentiation, and cell-dependency readouts together.